Xamoterol

From WikiMD's Wellnesspedia

Xamoterol is a cardiac stimulant that acts on beta-1 adrenergic receptors. It was developed by Allen & Hanburys and first marketed in 1988. Xamoterol has a unique mechanism of action, known as partial agonism. This means it can both stimulate and block beta-1 adrenergic receptors, depending on the circumstances.

Pharmacology[edit | edit source]

Xamoterol, chemically known as 5-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-3,4-dihydro-2(1H)-quinolinone, is a beta-1 adrenergic receptor partial agonist. This means it can both stimulate and block these receptors, depending on the circumstances. This unique mechanism of action allows it to increase cardiac output without significantly increasing heart rate or blood pressure.

Clinical Use[edit | edit source]

Xamoterol was developed for the treatment of heart failure. It was first marketed in 1988 by Allen & Hanburys, a British pharmaceutical company. However, it was withdrawn from the market in 1990 due to concerns about its safety and efficacy.

Side Effects[edit | edit source]

Like other cardiac stimulants, xamoterol can cause a range of side effects. These may include palpitations, tachycardia, angina pectoris, and arrhythmia. In some cases, these side effects can be severe and may require medical attention.

See Also[edit | edit source]

References[edit | edit source]


Xamoterol Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD